Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.34 EUR | -1.58% |
|
+4.37% | +41.56% |
11/07 | BAYER AG : Jefferies reiterates its Neutral rating | ZD |
11/07 | Health Rounds: Experimental Bayer drug eases menopause-like symptoms from breast cancer therapy | RE |
Projected Income Statement: Bayer AG
Annual
Quarterly
Halfyear
Annual
Quarterly
Halfyear
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 41,400 | 44,081 | 50,739 | 47,637 | 46,606 | 45,911 | 46,672 | 47,550 |
Change | - | 6.48% | 15.1% | -6.11% | -2.16% | -1.49% | 1.66% | 1.88% |
EBITDA 1 | 11,461 | 11,179 | 13,513 | 11,706 | 10,123 | 9,387 | 9,721 | 10,115 |
Change | - | -2.46% | 20.88% | -13.37% | -13.52% | -7.27% | 3.55% | 4.05% |
EBIT 1 | 7,095 | 7,295 | 9,257 | 7,589 | 5,436 | 5,219 | 5,572 | 5,951 |
Change | - | 2.82% | 26.9% | -18.02% | -28.37% | -3.99% | 6.75% | 6.82% |
Interest Paid 1 | -1,081 | -1,307 | -2,342 | -2,233 | -2,263 | -1,845 | -1,754 | -1,673 |
Earnings before Tax (EBT) 1 | -17,250 | 2,046 | 4,670 | -1,621 | -2,334 | 2,234 | 3,082 | 3,654 |
Change | - | 111.86% | 128.25% | -134.71% | -43.99% | 195.73% | 37.93% | 18.56% |
Net income 1 | -10,495 | 1,000 | 4,150 | -2,941 | -2,552 | 2,002 | 2,646 | 3,213 |
Change | - | 109.53% | 315% | -170.87% | 13.23% | 178.44% | 32.2% | 21.42% |
Announcement Date | 25/02/21 | 01/03/22 | 28/02/23 | 05/03/24 | 04/03/25 | - | - | - |
1EUR in Million
Estimates
Forecast Balance Sheet: Bayer AG
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | 37,575 | 32,966 | 31,273 | 34,263 | 32,354 | 30,997 | 27,694 | 24,749 |
Change | - | -12.27% | -5.14% | 9.56% | -5.57% | -4.19% | -10.66% | -10.63% |
Announcement Date | 25/02/21 | 01/03/22 | 28/02/23 | 05/03/24 | 04/03/25 | - | - | - |
1EUR in Million
Estimates
Cash Flow Forecast: Bayer AG
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|---|---|---|---|
CAPEX 1 | 2,418 | 2,611 | 2,949 | 2,751 | 2,778 | 2,663 | 2,787 | 2,817 |
Change | - | 7.98% | 12.95% | -6.71% | 0.98% | -4.14% | 4.67% | 1.06% |
Free Cash Flow (FCF) 1 | 2,485 | 2,478 | 4,144 | 2,366 | 4,590 | 2,729 | 3,922 | 4,227 |
Change | - | -0.28% | 67.23% | -42.91% | 94% | -40.54% | 43.7% | 7.78% |
Announcement Date | 25/02/21 | 01/03/22 | 28/02/23 | 05/03/24 | 04/03/25 | - | - | - |
1EUR in Million
Estimates
Forecast Financial Ratios: Bayer AG
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
EBITDA Margin (%) | 27.68% | 25.36% | 26.63% | 24.57% | 21.72% | 20.45% | 20.83% | 21.27% |
EBIT Margin (%) | 17.14% | 16.55% | 18.24% | 15.93% | 11.66% | 11.37% | 11.94% | 12.52% |
EBT Margin (%) | -41.67% | 4.64% | 9.2% | -3.4% | -5.01% | 4.87% | 6.6% | 7.68% |
Net margin (%) | -25.35% | 2.27% | 8.18% | -6.17% | -5.48% | 4.36% | 5.67% | 6.76% |
FCF margin (%) | 6% | 5.62% | 8.17% | 4.97% | 9.85% | 5.94% | 8.4% | 8.89% |
FCF / Net Income (%) | -23.68% | 247.8% | 99.86% | -80.45% | -179.86% | 136.33% | 148.19% | 131.54% |
Profitability | ||||||||
ROA | -8.63% | 0.84% | 3.39% | -2.44% | -2.25% | 0.57% | 1.67% | 2.49% |
ROE | 16.15% | 20.14% | 21.74% | 17.52% | 15.32% | 13.48% | 13.43% | 13.83% |
Financial Health | ||||||||
Leverage (Debt/EBITDA) | 3.28x | 2.95x | 2.31x | 2.93x | 3.2x | 3.3x | 2.85x | 2.45x |
Debt / Free cash flow | 15.12x | 13.3x | 7.55x | 14.48x | 7.05x | 11.36x | 7.06x | 5.86x |
Capital Intensity | ||||||||
CAPEX / Current Assets (%) | 5.84% | 5.92% | 5.81% | 5.77% | 5.96% | 5.8% | 5.97% | 5.92% |
CAPEX / EBITDA (%) | 21.1% | 23.36% | 21.82% | 23.5% | 27.44% | 28.37% | 28.67% | 27.85% |
CAPEX / FCF (%) | 97.3% | 105.37% | 71.16% | 116.27% | 60.52% | 97.57% | 71.07% | 66.64% |
Items per share | ||||||||
Cash flow per share 1 | 4.991 | 5.18 | 7.22 | 5.209 | 7.5 | 5.906 | 7.143 | 7.487 |
Change | - | 3.79% | 39.38% | -27.86% | 43.99% | -21.25% | 20.95% | 4.81% |
Dividend per Share 1 | 2 | 2 | 2.4 | 0.11 | 0.11 | 0.1104 | 0.6573 | 1.172 |
Change | - | 0% | 20% | -95.42% | 0% | 0.37% | 495.34% | 78.36% |
Book Value Per Share 1 | 31.07 | 33.61 | 39.47 | 33.52 | 32.48 | 34.41 | 37 | 39.39 |
Change | - | 8.18% | 17.42% | -15.08% | -3.09% | 5.95% | 7.52% | 6.46% |
EPS 1 | -10.68 | 1.02 | 4.22 | -2.99 | -2.6 | 1.517 | 2.38 | 2.989 |
Change | - | 109.55% | 313.73% | -170.85% | 13.04% | 158.35% | 56.86% | 25.58% |
Nbr of stocks (in thousands) | 9,82,424 | 9,82,424 | 9,82,424 | 9,82,424 | 9,82,424 | 9,82,424 | 9,82,424 | 9,82,424 |
Announcement Date | 25/02/21 | 01/03/22 | 28/02/23 | 05/03/24 | 04/03/25 | - | - | - |
1EUR
Estimates
2025 * | 2026 * | |
---|---|---|
P/E ratio | 18x | 11.5x |
PBR | 0.79x | 0.74x |
EV / Sales | 1.26x | 1.17x |
Yield | 0.4% | 2.4% |
More valuation ratios
* Estimated data
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
27.34EUR
Average target price
28.66EUR
Spread / Average Target
+4.81%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BAYN Stock
- Financials Bayer AG
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition